Is it a Good Time to Buy This Cannabis Stock Valued at $1 Billion?

Can Charlott’s Web Holdings Inc (TSXV:CWEB) leverage its leadership in hemp to gain traction and increase market share?

| More on:
Female scientist in a hemp field checking plants and flowers, alternative herbal medicine concept

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Shares of leading cannabis company Charlotte’s Web Holdings (TSXV:CWEB) are trading at $22.78 per share. The stock was publicly listed in September 2018. It rose from $14.45 in September last year to $33.77 in April 2019. CWEB is trading 116% above its 52-week low and 33% below its 52-week high.

Charlotte’s Web is a market leader in the production and distribution of hemp-based CBD (cannabidiol) products. It’s a vertically integrated company and is focused on creating hemp health supplements.

So, is the stock a good buy at the current price? Let’s have a look at CWEB’s revenue and growth drivers.

Solid revenue growth

CWEB grew sales by 74% from $40 million in 2017 to $70 million in 2018. Gross profit rose 75% from $30 million in 2017 to $52 million in 2018. The gross margin was 75% of sales. Adjusted EBITDA rose from $14.3 million in 2017 to $21.1 million in 2018.

In the second quarter of 2019, CWEB sales grew 45% year over year to $25 million. The gross margin was 75% at $18.8 million. Adjusted EBITDA accounted for 16% of sales at $3.9 million, while net income was 9% of revenue at $2.2 million. CWEB reported earnings per share of $0.02.

In fiscal 2019, CWEB estimates sales between $120 million and $170 million. The EBITDA is forecast between 30% and 35% for 2019.

Why is CWEB management optimistic about long-term growth?

Sales from retail outlets accounted for 53% of total second-quarter sales for the firm. The company has increased total retail locations that carry its products from 1,926 in the second quarter of 2018 to 7,871 in the second quarter of 2019. It is optimistic about growth, as the FDA continues to work with the hemp industry on product regulations.

During the earnings call, company CEO Deanie Elsner stated the following:

“We have been experiencing increased sales through both our e-commerce and retail sales channels. Top tier mass retailers are entering the market as several national grocery and drugstore brands have announced their CBD plans. The majority of these are now carrying Charlotte’s Web products. This is a significant development for the hemp CBD category.”

Focus on the retail health channel

We have seen that CWEB aims to gain traction in the cannabis health and wellness segment. Its products support Americans with a variety of needs. CWEB’s products support people experiencing exercise-induced inflammation. It has claimed that 183 million Americans exercise and are likely to feel effects of body strain.

Further, CWEB’s products also look to provide solutions for healthy sleep cycles and stress. Around 66.7 million Americans experience insomnia, while 40 million are diagnosed with stress disorders.

The company has increased its retail uptake in the natural health channel. Several leading retailers such as Kroger and CVS have added Charlotte’s Web products in the second quarter.

The verdict

Cannabis companies are banking heavily on the growing demand for products in North America and international markets. In order to support this demand, CWEB has increased its total acres planted for 2019 to 862 from 300 at the end of 2018. The hemp harvested last year from 300 acres totaled 675,000 pounds.

In the last quarter, CWEB introduced new products, such as the hemp-extract CBD gummies and a new 12 SKU pet product line. It has signed up distribution partnerships for its pet line with Pacific Pet and Pet Food Experts.

CWEB remains confident of gaining traction, as consumer awareness and interest in CBD continues to grow. It expects to onboard large retailers across several locations in the coming months. The company is valued at $1 billion, which is 6.7 times 2019 sales. The valuation is not too expensive compared to those of peer companies.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

The Motley Fool owns shares of Charlotte's Web Holdings. Fool contributor Aditya Raghunath has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »